Algan O, Jamgade A, Ali I, Christie A, Thompson J, Thompson D, Ahmad S, Herman T
Oklahoma UniversityHealth Science Ctr., Oklahoma City, OK.
Med Phys. 2012 Jun;39(6Part9):3699. doi: 10.1118/1.4735044.
Evaluate the dosimetric impact of daily setup error and inter-fraction organ motion on the radiation treatment plan.
Twelve patients undergoing definitive IMRT treatments for prostate cancer were evaluated. All patients underwent fiducial marker placement prior to treatment planning CT scan, and were treated to a dose of 8100cGy given in 45 fractions. We retrospectively created a plan for each treatment day that had a shift available. To calculate the dose the patient would have received with no setup correction, we mathematically 'negated' the shift by moving the isocenter in the opposite direction of the shift. The individualized daily plans were combined to generate an overall plan sum. The dose distribution from these uncorrected plans was compared to the actual treatment plans.
A total of 390 shifts were negated and their corresponding plans evaluated. The mean isocenter shift based on the location of the fiducial markers was 3.3±6.5mm to the right, 1.6±5.1mm posteriorly, and 1.0±5.0mm along the caudal direction. The mean D95 dose when setup error was corrected and uncorrected for the PTV8100 volume was 8089cGy and 7303cGy (p < 0.001) and for prostate volume was 8228cGy and 7844cGy (p < 0.002). The mean V95 values when setup error was corrected and uncorrected for the PTV8100 volume was 99.9% vs. 87.3% (p < 0.0001). At an individual level, the difference in D95 value approached 1200cGy for the prostate volume and 2000cGy for the PTV8100 volume. There was no statistically significant difference in the D35 parameter for the surrounding normal tissue except for the dose received by the right hip and the penile bulb.
This work indicates that significant underdosing, approaching 2000cGy for the PTV8100 volume, can occur as a Result of inaccurate patient setup, and emphasizes the importance of accurate patient setup and target localization.
评估每日摆位误差和分次间器官运动对放射治疗计划的剂量学影响。
对12例接受前列腺癌根治性调强放疗的患者进行评估。所有患者在治疗计划CT扫描前均植入了基准标记,并接受了45次分割、总剂量为8100cGy的治疗。我们回顾性地为每个有摆位偏差的治疗日制定了一个计划。为了计算未进行摆位校正时患者所接受的剂量,我们通过将等中心沿与摆位相反的方向移动,在数学上“抵消”了摆位偏差。将个体化的每日计划合并以生成总体计划总和。将这些未校正计划的剂量分布与实际治疗计划进行比较。
总共抵消了390次摆位偏差并评估了其相应计划。基于基准标记位置的平均等中心偏差为向右3.3±6.5mm、向后1.6±5.1mm以及沿尾侧方向1.0±5.0mm。对于PTV8100体积,校正和未校正摆位误差时的平均D95剂量分别为8089cGy和7303cGy(p < 0.001),对于前列腺体积分别为8228cGy和7844cGy(p < 0.002)。对于PTV8100体积,校正和未校正摆位误差时的平均V95值分别为99.9%和87.3%(p < 0.0001)。在个体水平上,前列腺体积的D95值差异接近1200cGy,PTV8100体积的差异接近2000cGy。除了右髋部和阴茎球部所接受的剂量外,周围正常组织的D35参数无统计学显著差异。
这项研究表明,由于患者摆位不准确,PTV8100体积可能出现接近2000cGy的显著剂量不足,强调了准确患者摆位和靶区定位的重要性。